Bharat Immunologicals & Biologicals (BOM:524663) Total Liabilities : ₹1,094.23 Mil (As of Sep. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Bharat Immunologicals & Biologicals Total Liabilities?

Bharat Immunologicals & Biologicals's Total Liabilities for the quarter that ended in Sep. 2023 was ₹1,094.23 Mil.

Bharat Immunologicals & Biologicals's quarterly Total Liabilities declined from Mar. 2023 (₹1,004.33 Mil) to Jun. 2023 (₹0.00 Mil) but then increased from Jun. 2023 (₹0.00 Mil) to Sep. 2023 (₹1,094.23 Mil).

Bharat Immunologicals & Biologicals's annual Total Liabilities increased from Mar. 2021 (₹699.44 Mil) to Mar. 2022 (₹1,073.76 Mil) but then declined from Mar. 2022 (₹1,073.76 Mil) to Mar. 2023 (₹1,004.33 Mil).

Bharat Immunologicals & Biologicals Total Liabilities Historical Data

The historical data trend for Bharat Immunologicals & Biologicals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bharat Immunologicals & Biologicals Total Liabilities Chart

Bharat Immunologicals & Biologicals Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Total Liabilities

Get a 7-Day Free Trial

942.83

1,063.56

699.44

1,073.76

1,004.33

Bharat Immunologicals & Biologicals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Total Liabilities	Get a 7-Day Free Trial															1,136.44	-	1,004.33	-	1,094.23

Bharat Immunologicals & Biologicals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bharat Immunologicals & Biologicals's Total Liabilities for the fiscal year that ended in Mar. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	940.424	+	(0	+	6.3948846218409E-14
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	63.906)
	=	1,004.33

Total Liabilities	=	Total Assets (A: Mar. 2023 )	-	Total Equity (A: Mar. 2023 )
	=	1886.473	-	882.143
	=	1,004.33

Bharat Immunologicals & Biologicals's Total Liabilities for the quarter that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	990.548	+	(35	+	-0.42199999999988
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	69.1)
	=	1,094.23

Total Liabilities	=	Total Assets (Q: Sep. 2023 )	-	Total Equity (Q: Sep. 2023 )
	=	1881.313	-	787.087
	=	1,094.23

Bharat Immunologicals & Biologicals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Bharat Immunologicals & Biologicals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Bharat Immunologicals & Biologicals (BOM:524663) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bharat Immunologicals & Biologicals Corp Ltd (BOM:524663) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Village Chola, BIBCOL, OPV Plant, Bulandshahar, UP, IND, 203203

Website

http://www.bibcol.sciencecentral.in

Bharat Immunologicals & Biologicals Corp Ltd is an India-based biotechnology company. It primarily manufactures Oral polio vaccines. In addition, the company also manufactures zinc tablets, diarrhea management kits, and Ready to Use Therapeutic Food (RUTF). It also manufactures nutraceuticals and biological products for the treatment of health deficiencies and disorders. The firm is organized into three segments: Oral Polio Vaccine, Zinc Tablets, and BIB VIT, BIBSANIT. The group principally operates in India and generates the majority of its revenue from sales of Oral polio vaccines.

Bharat Immunologicals & Biologicals (BOM:524663) Headlines

No Headlines